Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Official title:
This study aims to investigate the role of Hypoxia Inducible Factor (HIF) and autophagy-related genes in the pathogenesis of vitiligo among Egyptian patients in the Sohag Governorate. It will explore the presence of HIF, defects in autophagy-related genes, and their cross-interaction in vitiligo. A control group of participants without vitiligo will also be included for comparison.
Key Details
- Age Range: 18 to 75 years
- Study Population: Patients with non-segmental vitiligo and a healthy control group
Inclusion Criteria
- Adults aged 18 years and older
- Diagnosed with non-segmental vitiligo
- Control group participants without vitiligo
Exclusion Criteria
- Pregnant individuals
- Patients with chronic inflammatory skin disorders
- Use of antioxidants or anti-inflammatory drugs
- Recent topical or systemic vitiligo treatment (within the last 4 weeks)
- Presence of other autoimmune diseases or diabetes mellitus
Location: Sohag, Egypt
For a complete list of inclusion and exclusion criteria, interested individuals should contact the study team or visit the official ClinicalTrials.gov page (NCT06410898). Only the research staff can determine if a person fully qualifies for the study.
Start date: 2024-04-25
Completion date: 2024-07-25
Contact: Rania H Metwally
Tel.: 01018845428
Email: rania_hassan_post@med.sohag.edu.eg
Link: https://clinicaltrials.gov/study/NCT06410898
FAQOther Questions
- Shall I take vitamin D for my vitiligo?
Vitamin D plays a central role in the prevention of different inflammatory and chronic diseases. Consuming 1,000–4,000 IU (25–100 mcg) of vitamin D3 daily should be ideal for mo...
- Does vitiligo increase the risk of skin cancer?
No, it does not. Despite common misconceptions, people with vitiligo are actually at a lower risk of developing skin cancer—including both nonmelanoma skin cancer (NMSC) and mal...
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.